| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.30B | 1.13B | 1.39B | 1.39B | 1.35B | 1.09B |
| Gross Profit | 819.54M | 719.22M | 911.37M | 662.60M | 689.93M | 553.44M |
| EBITDA | 405.50M | 441.97M | 596.91M | 592.40M | 602.84M | 474.13M |
| Net Income | 290.25M | 206.90M | 315.80M | 315.64M | 305.25M | 284.63M |
Balance Sheet | ||||||
| Total Assets | 1.08B | 935.91M | 1.22B | 1.30B | 1.28B | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 471.42M | 386.80M | 567.40M | 656.85M | 454.37M | 532.89M |
| Total Debt | 238.70M | 216.65M | 268.73M | 240.35M | 311.07M | 261.60M |
| Total Liabilities | 634.89M | 557.18M | 725.00M | 684.02M | 786.93M | 795.52M |
| Stockholders Equity | 452.19M | 379.95M | 497.51M | 612.27M | 494.27M | 684.85M |
Cash Flow | ||||||
| Free Cash Flow | 358.30M | 298.23M | 445.50M | 533.81M | 372.16M | 527.69M |
| Operating Cash Flow | 412.48M | 332.88M | 497.12M | 560.55M | 516.71M | 605.91M |
| Investing Cash Flow | -235.97M | -171.93M | 162.56M | -222.51M | 8.05M | -300.82M |
| Financing Cash Flow | -517.69M | -477.95M | -520.97M | -335.02M | -565.97M | -394.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$612.50M | 7.31 | 25.63% | 6.04% | -1.62% | -10.07% | |
69 Neutral | HK$1.84B | 39.16 | 54.98% | ― | 45.40% | 12.38% | |
66 Neutral | HK$1.80B | 8.68 | 47.16% | 11.60% | -19.05% | -34.49% | |
59 Neutral | HK$368.00M | 34.72 | 7.45% | ― | -18.43% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$63.31M | ― | -2.50% | ― | -0.31% | 47.17% |
Perfect Medical Health Management Limited announced the results of its Annual General Meeting held on August 8, 2025. All proposed resolutions, including the adoption of financial statements, approval of a final dividend, re-election of directors, and re-appointment of auditors, were passed with overwhelming support. The approval of mandates for issuing and repurchasing shares indicates the company’s strategic flexibility in managing its capital structure, which could impact its market positioning and shareholder value.